Skip to main content
SpringerLink
Log in

Characteristics of Lipoprotein(a)-Containing Circulating Immune Complexes as Markers of Coronary Heart Disease

  • MICROBIOLOGY AND IMMUNOLOGY
  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

We studied the composition of circulating immune complexes precipitated in the presence of various concentrations of polyethylene glycol in patients with coronary heart disease (CHD) and high concentration of lipoprotein(a) — Lp(a). Precipitation of highly purified Lp(a) preparation with polyethylene glycol was evaluated. The contents of Lp(a), autoantibodies to Lp(a), IgG, and IgM in circulating immune complexes isolated from the sera of donors and CHD patients with normal and high levels of Lp(a) were measured. Circulating immune complexes containing Lp(a) were detected in the plasma of CHD patients with high Lp(a) concentrations. The presence of high concentrations of Lp(a), autoantibodies to Lp(a), and circulating immune complexes in CHD patients suggests that immunological factor contributes to high atherothrombogenicity of Lp(a).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Afanas’eva OI, Adamova IYu, Benevolenskaya GF, Pokrovskii SN. Comparison of three methods of isolating lipoprotein (a) from human blood plasma. Bull. Exp. Biol. Med. 1992;113(3):345-348.

    Google Scholar 

  2. Afanas’eva OI, Adamova IYu, Benevolenskaya GF, Pokrovskii SN. Enzyme immunoassay of lipoprotein(a). Bull. Exp. Biol. Med. 1995;120(4):1030-1033.

    Article  Google Scholar 

  3. Afanasieva OI, Klesareva EA, Levashov PA, Berestetskaya YuV, Ezhov MV, Artemieva NV, Pokrovsky SN. Autoantibodies against Lipoprotein(a) in patients with coronary heart disease. Kardiologiya. 2014;54(6):4-8. Russian.

  4. Gurevich VS, Urazgildeeva SA, Buthashvili MI, Vasina LV. Evolution of the knowledge about pro- and antiatherogenic properties of lipoproteins. Ateroskleroz Dislipidemii. 2012;(4):54-63. Russian.

  5. Moskalev AV, Tsugan VN, Chechetkin AV. Laboratory Methods for Immune Status Evaluation. Medical Laboratory Technologies. Karpishchenko AI, ed. Moscow, 2013. Vol. 2. P. 243-337. Russian.

  6. Nemov VV, Popkova MI. Patent RF No. 2415430. Method for Detecting Circulating Immune Complexes. Bull. No. 9. Published March 27, 2011.

  7. Bergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, Binder CJ, Hörkkö S, Krauss RM, Chapman MJ, Witztum JL, Tsimikas S. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 2008;49(10):2230-2239.

    Article  CAS  PubMed  Google Scholar 

  8. Jin Y, Manabe T. Analysis of PEG-fractionated high-molecularmass proteins in human plasma by non-denaturing micro 2-DE and MALDI-MS PMF. Electrophoresis 2009;30(20):3613-3621.

    Article  CAS  PubMed  Google Scholar 

  9. Laczik R, Szodoray P, Veres K, Szomják E, Csípo I, Sipka S Jr, Shoenfeld Y, Szekanecz Z, Soltész P. Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. Lupus. 2011;20(7):730-735.

    Article  CAS  PubMed  Google Scholar 

  10. Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J. Atheroscler. Thromb. 2013;20(10):743-754.

    Article  CAS  PubMed  Google Scholar 

  11. Missala I, Kassner U, Steinhagen-Thiessen E. Systematic literature review of the a of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int. J. Rheumatol. 2012;2012. ID 480784. doi: 10.1155/2012/480784.

  12. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010;31(23):2844-2853.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Oda M, Uchiyama S, Noda M, Nishi Y, Koga M, Mayanagi K, Robinson C.V, Fukui K, Kobayashi Y, Morikawa K, Azuma T. Effects of antibody affinity and antigen valence on molecular forms of immune complexes. Mol. Immunol. 2009;47(2-3):357-364.

    Article  CAS  PubMed  Google Scholar 

  14. Riches K, Porter KE. Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol. 2012;2012. ID 923289.

  15. Virella G, Lopes-Virella MF. Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis. 2008;200(2):239-246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Russian Cardiology Research and Production Center, Ministry of Health of the Russian Federation, Moscow, Russia

    E. A. Klesareva, O. I. Afanas’eva, V. V. Donskikh, I. Yu. Adamova & S. N. Pokrovskii

Authors
  1. E. A. Klesareva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. I. Afanas’eva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. V. Donskikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Yu. Adamova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. N. Pokrovskii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. A. Klesareva.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 162, No. 8, pp. 195-201, August, 2016

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klesareva, E.A., Afanas’eva, O.I., Donskikh, V.V. et al. Characteristics of Lipoprotein(a)-Containing Circulating Immune Complexes as Markers of Coronary Heart Disease. Bull Exp Biol Med 162, 231–236 (2016). https://doi.org/10.1007/s10517-016-3583-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-016-3583-z

Key Words

Search

Navigation